Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments. A PubMed literature search was performed using the following keywords: Helicobacter pylori, infection, reinfection, antibiotic resistance, bismuth, proton pump inhibitors, vonoprazan, susceptibility, quintuple therapy, dual therapy, and probiotic. The prevalence of H. pylori has remained high in some areas despite the decreasing trend of H. pylori prevalence observed over time. Additionally, the H. pylori reinfection rate has varied in different countries due to socioeconomic and hygienic conditions. H. pylori monoresistance to clarithromycin, metronidazole or levofloxacin was common in most countries. However, the prevalence of amoxicillin and tetracycline resistance has remained low. Because H. pylori infection and reinfection present serious challenges and because H. pylori resistance to clarithromycin, metronidazole or levofloxacin remains high in most countries, the selection of an efficient regimen to eradicate H. pylori is critical. Currently, bismuth–containing quadruple therapies still achieve high eradication rates. Moreover, susceptibility–based therapies are alternatives because they may avoid the use of unnecessary antibiotics. Novel regimens, e.g., vonoprazan–containing triple therapies, quintuple therapies, high–dose dual therapies, and standard triple therapies with probiotics, require further studies concerning their efficiency and safety for treating H. pylori.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kyoto global consensus report on Helicobacter pylori gastritis
Sugano, K., Tack, J., Kuipers, E. J., Graham, D. Y., El-Omar, E. M., Miura, S., Haruma, K., Asaka, M., Uemura, N., & Malfertheiner, P. (2015) · Gut · doi:10.1136/gutjnl-2015-309252 · Cited by 1,876
Jakobsson, H. E., Jernberg, C., Andersson, A. F., Sjölund-Karlsson, M., Jansson, J. K., & Engstrand, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009836 · Cited by 1,160
Nista, E. C., Candelli, M., Cremonini, F., Cazzato, I. A., Zocco, M. A., Franceschi, F., Cammarota, G., Gasbarrini, G., & Gasbarrini, A. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02274.x · Cited by 212 · cited 2×
“…shown the important role of Pbs (mainly Lactobacillus or Saccharomyces boulardii or Bacillus clausii) in improving the H. pylori eradication rate (Nista et al., 2004; Tong et al., 2007; Zou et al., 2009; Szajewska et al., 2010, 2015; Wang et al., 2013; Dang et al., 2014; Zhang M. M. et al.,…”
BackgroundThe Prevalence of Helicobacter pylori Remains High in African American and Hispanic Veterans
Nguyen, T., Ramsey, D., Graham, D., Shaib, Y., Shiota, S., Velez, M., Cole, R., Anand, B., Vela, M., & El‐Serag, H. B. (2015) · Helicobacter · doi:10.1111/hel.12199 · Cited by 56 · cited 4×
“(Okamura et al., 2014; Nishizawa et al., 2015; Sugimoto et al., 2015).”
BackgroundInfluential
Cited by
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications
Tshibangu-Kabamba, E., & Yamaoka, Y. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00449-x · Cited by 517
Pathogenesis and clinical management of Helicobacter pylori gastric infection
Brito, B. B. D., Silva, F. A. F. D., Soares, A. S., Pereira, V. A., Santos, M. L. C., Sampaio, M. M., Neves, P. H. M., & Melo, F. F. D. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i37.5578 · Cited by 291
Metadata
- Authors
- Hu, Y., Zhu, Y., & Lu, N.-H.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2017-05-05
- Volume
- 7
- Pages
- 168-168
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W2611781744
- Cited by
- 175
- References
- 4
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. https://app.cochat.ai/papers/10.3389/fcimb.2017.00168
- The paper
- Hu, Y., Zhu, Y., & Lu, N.-H. (2017). Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2017.00168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.